Advertisement

Topics

Positive data from IMV's midstage DLBCL trial

05:58 EDT 13 Jun 2019 | SmartBrief

Vaccine developer IMV announced that its candidate DPX-Survivac showed a positive effect in its midstage trial as a treatment -More

Original Article: Positive data from IMV's midstage DLBCL trial

NEXT ARTICLE

More From BioPortfolio on "Positive data from IMV's midstage DLBCL trial"

Advertisement
Quick Search
Advertisement
Advertisement